NCT06488313View on ClinicalTrials.gov

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

PHASE2RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

September 1, 2026

Conditions
OTC DeficiencyOrnithine Transcarbamylase DeficiencyOTCD
Interventions
BIOLOGICAL

ARCT-810

ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).

Trial Locations (1)

20815

RECRUITING

Uncommon Cures, Chevy Chase

Sponsors
All Listed Sponsors
lead

Arcturus Therapeutics, Inc.

INDUSTRY